(29 days)
No
The document does not mention AI, ML, or related terms like deep learning or neural networks in the description of the device's functionality or software. The software is described as an acquisition, display, and analysis package, which are standard functions for medical imaging software and do not inherently imply AI/ML.
No.
The device is described as an imaging system used to aid in detecting, localizing, diagnosing, and staging diseases and disorders, as well as for radiotherapy treatment planning. It produces images but does not actively treat or directly interact with the body to cure, mitigate, or prevent disease.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that the device is intended "to aid in detecting, localizing, diagnosing, staging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders". It also mentions the use of SPECT and CT components as "stand-alone diagnostic imaging devices."
No
The device description explicitly states it consists of a SPECT scanner and an integrated hybrid x-ray CT and SPECT scanner, which are hardware components. While it includes software for image processing and analysis, it is not solely software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body, such as blood, urine, or tissue, to detect diseases or other conditions.
- Device Function: The Siemens Symbia Pro.specta VA20A Family is an imaging system (SPECT and CT). It works by detecting and imaging the distribution of radionuclides in the body (SPECT) or using x-ray transmission data to create cross-sectional images (CT). It does not perform tests on samples taken from the body.
- Intended Use: The intended use describes aiding in detecting, localizing, diagnosing, staging of lesions, tumors, disease and organ function through imaging. It also mentions radiotherapy treatment planning. These are all functions related to imaging and visualization within the body, not testing of external samples.
Therefore, the device falls under the category of medical imaging equipment, not In Vitro Diagnostics.
N/A
Intended Use / Indications for Use
The Siemens Symbia Pro.specta VA20A Family is intended for use by appropriately wained health care professionals to aid in detecting, localizing, diagnosing, staging of lesions, turnors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning or additional uses.
SPECT: The SPECT component is intended to detect or image the distribution of radionuclides in the body or organ (physiology), using the following techniques: planar imaging, and tomographic imaging for isotopes with energies up to 588 keV.
CT: The CT component is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data (anatomy) from either the same axial plane taken at different angles or spiral planes taken at different angles.
SPECT+CT: The SPECT and CT components used together acquire SPECT/CT images. The SPECT images can be corrected for attenuation with the CT images, and can be combined (image registration) to merge the patient's physiological (SPECT) and anatomical (CT) images.
Software: The SPECTsyngo software is an acquisition, display and analysis package intended to aid the clinician in the assessment and quantification of pathologies in images produced from SPECT, PET, CT, and other imaging modalities.
This CT system can be used for low dose lung cancer screening in high-risk populations **As defined by professional medical societies. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011; 365:395-409) and subsequent literature, for further information.
Product codes
KPS, JAK
Device Description
The Siemens Symbia Pro.specta VA20A Family consists of Single-Photon Emission Computed Tomography (SPECT) scanner and integrated hybrid x-ray Computed Tomography (CT) and SPECT scanner.
The SPECT subsystem images and measures the distribution of radiopharmaceuticals in humans for the purpose of determining various metabolic (molecular) and physiologic functions within the human body and integrates CT's anatomical detail for precise reference of the location of the metabolic activity.
The CT component produces cross-sectional images of the body by computer reconstruction of x-ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles.
The system can be used as an integrated SPECT and CT modality while also enabling independent functionality of SPECT and CT as stand-alone diagnostic imaging devices.
Siemens Symbia Pro.specta VA20A Family maintains the same intended use and indications for use as the commercially available Symbia Pro.specta VA10A family (K212604).
Symbia Pro.specta VA20A Family are hybrid modality imaging systems comprised of two separate but integrated components: a gamma camera (SPECT) and a CT. The gamma camera is based on hardware and software features that generate nuclear medicine images based on the uptake of radioisotope tracers in a patient's body. The CT system (spiral CT) is designed to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles.
The combination of SPECT and CT in a single device has several benefits. The SPECT subsystem images biochemical function while the CT subsystem images anatomy. The combination enables scans that not only indicate function, e.g., how active a tumor is, but precise localization, e.g., the precise location of that tumor in the body.
In addition, CT can be used to correct for the attenuation in SPECT acquisitions. Attenuation in SPECT is an unwanted side effect of the gamma rays scattering and being absorbed by tissue. This can lead to errors in the final image. The CT directly measures attenuation and can be used to create a 3D attenuation map of the patient which can be used to correct the SPECT images. The SPECT-CT scanner can be used to image and track how much dose was delivered to both the target and the surrounding tissue.
The systems consist of display equipment, data storage devices, patient and equipment supports and component parts and accessories.
Symbia Pro.specta VA20A release is the product name for the additional features to the approved Symbia Pro.specta VA10A Family (K212604). The Symbia Pro.specta VA20A devices are based on the Symbia Pro.specta VA10A Family. The difference lies in the additional features/changes. The Intended Purpose and fundamental scientific technology remain unchanged.
Proposed New Features for Symbia Pro.specta VA20A Family:
- . my Exam Satellite
Other changes: - . improvement of CT topogram planning
- enhanced QCI (Quality Control Image) projections
- bed height after reconfigure
- GUI change for radiopharmaceutical configuration
- Nuclear medicine raw data export
- GUI and configuration change for scan end beep
- Auto Export Tool improvements
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
SPECT, CT, PET, X-ray
Anatomical Site
Body or organ
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Appropriately trained health care professionals; Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing for the CT subsystem was included in the premarket notification for the CT subsystems (K211373) and there have been no changes affecting this testing.
Each CT subsystem is tested and passes the Applicable Performance Standards prior to shipment.
Symbia Pro.specta VA20A systems are designed in accordance with the 60601-1 series including all relevant collateral standards general (IEC 60601-1, 1-2, 1-3, etc.) and specific (IEC 60601-2-44). Performance testing is conducted according to NEMA NU-1. All Performance testing met the predetermined acceptance values.
Existing NEMA detector and collimator performance specifications do not change between the commercially available Symbia Pro.specta VA10A Family and proposed Symbia Pro.specta VA20A systems. There are no changes in the system design that could impact the SPECT performance specifications and the commercially available specifications still apply.
Bench testing performed on the CT subsystem is conducted in accordance with IEC 60601-2-44 and in accordance with US regulations including 21 CFR 1020.33, Computed Tomography (CT) equipment. This is unchanged from the commercially available SOMATOM go CT systems (K211373).
Risk analyses performed at Siemens Medical Solutions USA; Inc. are in compliance with the requirements of:
- IEC/ISO 14971 Medical Devices Application of Risk Management to Medical Devices
- IEC 62304 Medical Device Software Software Life-cycle Processes
Verification and validation of Siemens software is performed in accordance with documented procedures, test plans and specifications. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software verification, and system testing.
System and System Integration testing (validation) was carried out for all features of the project, and all planned test cases were executed.
Verification and Validation is performed to: - ensure the functionality described in the specifications are met,
- ensure the quality in the planning documentation is adhered to,
- ensure mitigations required by risk analysis are implemented, and appropriate
- identify additional issues that may be related to patient / operator safety, or effectiveness
- assure that the specifications are appropriate to fulfill the intended use of the system.
Symbia Pro.specta VA20A systems conform to applicable FDA recognized and international IEC, ISO and NEMA standards with regards to performance and safety as required by the respective SPECT FDA Guidance Documents. SPECT detector and CT performance is conducted according to NEMA NU-1, and the performance does not change from the predicate device.
Verification and validation of Siemens systems is performed in accordance with documented procedures, design and code reviews, test plans and specifications. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software validation and system testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1200 Emission computed tomography system.
(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue. Underneath the FDA logo is the word "ADMINISTRATION".
May 17, 2023
Siemens Medical Solutions USA, Inc. % Tabitha Estes Regulatory Affairs Specialist 810 Innovation Drive KNOXVILLE TN 37932
Re: K231102
Trade/Device Name: Symbia Pro.specta VA20A Family Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: Class II Product Code: KPS, JAK Dated: April 18, 2023 Received: April 18, 2023
Dear Tabitha Estes:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
D.K.
Daniel M. Krainak, Ph.D. Assistant Director Magnetic Resonance and Nuclear Medicine Team DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
K231102
Device Name Symbia Pro.specta VA20A Family
Indications for Use (Describe)
The Siemens Symbia Pro.specta VA20A Family is intended for use by appropriately wained health care professionals to aid in detecting, localizing, diagnosing, staging of lesions, turnors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning or additional uses.
SPECT: The SPECT component is intended to detect or image the distribution of radionuclides in the body or organ (physiology), using the following techniques: planar imaging, and tomographic imaging for isotopes with energies up to 588 keV.
CT: The CT component is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data (anatomy) from either the same axial plane taken at different angles or spiral planes taken at different angles.
SPECT+CT: The SPECT and CT components used together acquire SPECT/CT images. The SPECT images can be corrected for attenuation with the CT images, and can be combined (image registration) to merge the patient's physiological (SPECT) and anatomical (CT) images.
Software: The SPECTsyngo software is an acquisition, display and analysis package intended to aid the clinician in the assessment and quantification of pathologies in images produced from SPECT, PET, CT, and other imaging modalities.
This CT system can be used for low dose lung cancer screening in high-risk populations * *As defined by professional medical societies. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011; 365:395-409) and subsequent literature, for further information.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
as required by 21 CFR Part 807.87(h)
Identification of the Submitter
| Submitter: | Tabitha Estes
Regulatory Affairs Specialist
Siemens Molecular Solutions USA, Inc.
810 Innovation Drive
Knoxville, TN 37932 |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Manufacturer: | Siemens Medical Solutions USA, Inc.
Molecular Imaging
2501 North Barrington Road
Hoffman Estates, IL 60192 |
| Telephone Number: | (865) 804 - 4553 |
| Date of Submission: | April 18th, 2023 |
Identification of the product
| Device Proprietary Name: | Symbia Pro.specta VA20A Family | |
|---|---|---|
| Common Name: | Single-Photon Emission Computed Tomography (SPECT) | |
| System | ||
| Computed Tomography (CT) System | ||
| Classification Name: | Emission Computed Tomography System per 21 CFR | |
| 892.1200 | ||
| Computed Tomography X-Ray System per 21 CFR | ||
| 892.1750 | ||
| Product Code: | KPS and JAK | |
| Classification Panel: | Radiology | |
| Device Class: | Class II |
4
Marketed Devices to which Equivalence is claimed:
Predicate Device:
| Device Proprietary Name: | Symbia VA10A Family Update | |
|---|---|---|
| Common Name: | Single-Photon Emission Computed Tomography (SPECT) | |
| System | ||
| Computed Tomography (CT) System | ||
| Classification Name: | Emission Computed Tomography System per 21 CFR | |
| 892.1200 | ||
| Computed Tomography X-Ray System per 21 CFR | ||
| 892.1750 | ||
| Manufacturer: | Siemens Medical Solutions USA, Inc. | |
| Product Code: | KPS and JAK | |
| Classification Panel: | Radiology | |
| Device Class: | Class II | |
| 510(k) Number: | K212604 | |
| Reference Device: | ||
| Device Name and 510(k) | ||
| numbers: | Scan&GO, SOMATOM Go.Platform | |
| Common Name: | Computed Tomography X-Ray System | |
| Classification Name: | Computed Tomography X-Ray System per 21 CFR | |
| 892.1750 | ||
| Picture Archiving and Communications System per 21 CFR | ||
| 892.2050 | ||
| Manufacturer: | Siemens Healthcare GmbH | |
| Product Code: | LLZ, JAK | |
| Classification Panel: | Radiology | |
| Device Class: | Class II | |
| 510(k) Number: | K211373 | |
| Reference Device: | ||
| Device Name and 510(k) | ||
| numbers: | MI View&Go VA20A | |
| Common Name: | Image Processing Software | |
| Classification Name: | Picture Archiving and Communications System per 21 CFR | |
| 892.2050 | ||
| Manufacturer: | Siemens Medical Solution, USA, Inc. | |
| Product Code: | LLZ | |
| Classification Panel: | Radiology | |
| Device Class: | Class II | |
| 510(k) Number: | K222172 |
5
Device Description:
The Siemens Symbia Pro.specta VA20A Family consists of Single-Photon Emission Computed Tomography (SPECT) scanner and integrated hybrid x-ray Computed Tomography (CT) and SPECT scanner.
The SPECT subsystem images and measures the distribution of radiopharmaceuticals in humans for the purpose of determining various metabolic (molecular) and physiologic functions within the human body and integrates CT's anatomical detail for precise reference of the location of the metabolic activity.
The CT component produces cross-sectional images of the body by computer reconstruction of x-ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles.
The system can be used as an integrated SPECT and CT modality while also enabling independent functionality of SPECT and CT as stand-alone diagnostic imaging devices.
Siemens Symbia Pro.specta VA20A Family maintains the same intended use and indications for use as the commercially available Symbia Pro.specta VA10A family (K212604).
6
Symbia Pro.specta VA20A Family are hybrid modality imaging systems comprised of two separate but integrated components: a gamma camera (SPECT) and a CT. The gamma camera is based on hardware and software features that generate nuclear medicine images based on the uptake of radioisotope tracers in a patient's body. The CT system (spiral CT) is designed to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles.
The combination of SPECT and CT in a single device has several benefits. The SPECT subsystem images biochemical function while the CT subsystem images anatomy. The combination enables scans that not only indicate function, e.g., how active a tumor is, but precise localization, e.g., the precise location of that tumor in the body.
In addition, CT can be used to correct for the attenuation in SPECT acquisitions. Attenuation in SPECT is an unwanted side effect of the gamma rays scattering and being absorbed by tissue. This can lead to errors in the final image. The CT directly measures attenuation and can be used to create a 3D attenuation map of the patient which can be used to correct the SPECT images. The SPECT-CT scanner can be used to image and track how much dose was delivered to both the target and the surrounding tissue.
The systems consist of display equipment, data storage devices, patient and equipment supports and component parts and accessories.
Symbia Pro.specta VA20A release is the product name for the additional features to the approved Symbia Pro.specta VA10A Family (K212604). The Symbia Pro.specta VA20A devices are based on the Symbia Pro.specta VA10A Family. The difference lies in the additional features/changes. The Intended Purpose and fundamental scientific technology remain unchanged.
Proposed New Features for Symbia Pro.specta VA20A Family:
-
. my Exam Satellite
Other changes: -
. improvement of CT topogram planning
-
enhanced QCI (Quality Control Image) projections ●
-
bed height after reconfigure
-
GUI change for radiopharmaceutical configuration ●
-
Nuclear medicine raw data export ●
-
GUI and configuration change for scan end beep
-
Auto Export Tool improvements ●
7
| Features | Symbia Pro.specta VA20
(Subject Device) | Symbia Pro.specta VA10
(Predicate Device) |
|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| Intended/Indication For Use | Same | Same |
| Biocompatibility | Same | Same |
| Productivity Features | Same | Same |
| Optional
Pallets/Accessories/Collimators | Same | Same |
| MI View&GO updates | Inclusion of MI Neurology,
Auto Lung 3D and
syngo.MBF as well as
incremental improvements.
All changes are included in
K222172. | N/A |
| Operating System | Same | Same |
| Computer Systems additions | myExam Satellite has been
added as an additional
workplace computer. | N/A |
| Scan Planning Updates | For SPECT-first hybrid
workflows and CT-first
hybrid workflows where
planning is done by
positioning the patient under
the NM detectors, the
topogram planning has been
updated. | N/A |
| SPECT Software updates | TrueCalc has been added as a
Quantification method for
the Symbia Pro.specta Q3.
Enhanced QCI Projections
has been implemented. This
option will allow the user to
change the projection image
if they prefer different
parameters from the default
behavior.
Additional DICOM attributes
have also been included with
this software update.
A change has also been made
to the software on bed height
control. The bed will be
restored to the position it was
in prior to reconfiguration | N/A |
| | (applies to 180, 90, 76 and
CT). | |
| Export updates | Updates have been made to
the Auto Export Tool to
streamline the workflow.
Also, workflow
improvements to data export
has been made so that the
user can send SPECT raw
data and DICOM data to a
file system with one export
tool. | N/A |
| CT Software updates | ADMIRE (Advanced
Modelled Iterative
Reconstruction) for the
Symbia Pro.specta X7.
Additional features as included
in SOMATOM VA40
K211373. | N/A |
| Connectivity | Same | Same |
| SPECT Detectors | Same | Same |
| SPECT Gantry | Same | Same |
| CT Gantry updates | No changes as compared to
SOMATOM VA40 K211373. | N/A |
| Detector Performance and
Collimator Specifications | Same | Same |
| GUI Changes | Updates have been made to
the GUI for updates to the
radiopharmaceutical
configuration and the scan
end beep. | N/A |
The table below summarizes the differences between the subject and predicate devices.
8
Intended Use:
The Symbia Pro.specta systems are radiological imaging systems that combines a single photon emission computed tomography (SPECT) camera system for nuclear medicine images, and a computed tomography (CT) camera system for x-ray images.
The SPECT system is intended to detect the location and distribution of gamma ray radionuclides in the body and produce cross-sectional images through computer reconstruction of the data, and the CT system is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. The nuclear medicine images and the x-ray images may be registered and displayed in a fused format (overlaid in the same orientation) for the anatomical localization of the nuclear medicine data (that is, distribution of radiopharmaceuticals). The SPECT and CT portions of the
9
system may be used independently or in combination, and may include signal analysis and display equipment, patient and equipment support, radionuclide anatomical markers, component parts, and accessories. The SPECT and CT images may be transferred to other systems for radiation therapy planning or additional uses.
Indications for Use:
The Symbia Pro.specta systems are intended for use by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging of lesions, turnors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning or additional uses.
SPECT: The SPECT component is intended to detect or image the distribution of radionuclides in the body or organ (physiology), using the following techniques: planar imaging, whole body imaging, and tomographic imaging for isotopes with energies up to 588 keV.
CT: The CT component is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data (anatomy) from either the same axial plane taken at different angles or spiral planes taken at different angles.
SPECT+CT: The SPECT and CT components used together acquire SPECT/CT images. The SPECT images can be corrected for attenuation with the CT images, and can be combined (image registration) to merge the patient's physiological (SPECT) and anatomical (CT) images.
Software: The SPECTsyngo software is an acquisition, display and analysis package intended to aid the clinician in the assessment and quantification of pathologies in images produced from SPECT. PET. CT. and other imaging modalities.
This CT system can be used for low dose lung cancer screening in high risk populations.*
- As defined by professional medical societies. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011; 365:395-409) and subsequent literature, for further information.
There are no known contraindications.
Technological Characteristics:
Performance Testing:
Performance testing for the CT subsystem was included in the premarket notification for the CT subsystems (K211373) and there have been no changes affecting this testing.
Each CT subsystem is tested and passes the Applicable Performance
Standards prior to shipment:
- · 21 CFR 1020.30 (a) Applicability
- · 21 CFR 1020.30 (b)(36)(iii)-(v) Technique Factors
10
- · 21 CFR 1020.30 (b)(58)-(62) CT, Scan, Scan Time, Tomogram, Dose
- · 21 CFR 1020.30 (h)(3)(vi)-(viii) Information to be provided for users
- · 21 CFR 1020.33 Computed Tomography (CT) equipment
- · 21 CFR 1040.10 Laser Products
- · 21 CFR 1040.11 Specific purpose laser products
Symbia Pro.specta VA20A systems are designed in accordance with the 60601-1 series including all relevant collateral standards general (IEC 60601-1, 1-2, 1-3, etc.) and specific (IEC 60601-2-44). Performance testing is conducted according to NEMA NU-1. All Performance testing met the predetermined acceptance values.
| Detector Specifications | ||
|---|---|---|
| Intrinsic spatial resolution - Tc99m | SPECT | 3/8" |
| FWHM in CFOV | SPECT | ≤3.84 mm |
| FWHM in UFOV | SPECT | ≤3.94 mm |
| FWTM in CFOV | SPECT | ≤7.54 mm |
| FWTM in UFOV | SPECT | ≤7.74 mm |
| Intrinsic spatial linearity - Tc99m | SPECT | |
| Differential in CFOV | SPECT | ≤0.24 mm |
| Differential in UFOV | SPECT | ≤0.24 mm |
| Absolute in CFOV | SPECT | ≤0.44 mm |
| Absolute in UFOV | SPECT | ≤0.7 mm |
| Intrinsic energy resolution | SPECT | |
| FWHM in CFOV | SPECT | ≤9.9% |
| Intrinsic flood field uniformity (uncorrected) - | ||
| Tc99m | SPECT | |
| Differential in CFOV | SPECT | ≤2.5% |
| Differential in UFOV | SPECT | ≤2.7% |
| Integral in CFOV | SPECT | ≤2.9% |
| Integral in UFOV | SPECT | ≤3.7% |
Existing NEMA detector and collimator performance specifications do not change between the commercially available Symbia Pro.specta VA10A Family and proposed Symbia Pro.specta VA20A systems. There are no changes in the system design that could impact the SPECT performance specifications and the commercially available specifications still apply.
11
Bench testing performed on the CT subsystem is conducted in accordance with IEC 60601-2-44 and in accordance with US regulations including 21 CFR 1020.33, Computed Tomography (CT) equipment. This is unchanged from the commercially available SOMATOM go CT systems (K211373).
Risk analyses performed at Siemens Medical Solutions USA; Inc. are in compliance with the requirements of:
- IEC/ISO 14971 Medical Devices Application of Risk Management to Medical Devices ●
- IEC 62304 Medical Device Software Software Life-cycle Processes ●
There is no significant difference in the risks imposed by this system and the risks associated with the predicate devices. The product Risk Management Team has reviewed and verified that all risks identified in the Symbia Pro.specta VA20A Product Risk Analysis has been adequately mitigated and the individual and overall residual risks are reduced as far as possible.
Verification and validation of Siemens software is performed in accordance with documented procedures, test plans and specifications. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software verification, and system testing.
System and System Integration testing (validation) was carried out for all features of the project, and all planned test cases were executed.
Verification and Validation is performed to:
- ensure the functionality described in the specifications are met, .
- . ensure the quality in the planning documentation is adhered to,
- ensure mitigations required by risk analysis are implemented, and appropriate ●
- . identify additional issues that may be related to patient / operator safety, or effectiveness
- . assure that the specifications are appropriate to fulfill the intended use of the system.
Safety and Effectiveness:
The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of the device.
Risk Management is ensured via a risk analysis in compliance with ISO 14971 to identify and provide mitigation to potential hazards beginning early in the design cycle and continuing throughout the development of the product.
Cybersecurity information in accordance with FDA Guidance documents issued on October 2, 2014, has been provided. The Symbia Pro.specta VA20A systems software has specific cybersecurity controls to prevent unauthorized access, modifications, misuse or denial of use.
Additionally, controls are enabled to prevent the unauthorized use of information that is stored, accessed or transferred between the Symbia Pro.specta VA20A systems and external devices.
12
Siemens Medical Solutions, USA Inc. adheres to recognized and established industry standards such as IEC 60601-1 series and 21 CFR 1020.30 and 21 CFR 1020.33 to minimize electrical, mechanical and radiation hazards.
Symbia Pro.specta VA20A systems conform to applicable FDA recognized and international IEC, ISO and NEMA standards with regards to performance and safety as required by the respective SPECT FDA Guidance Documents. SPECT detector and CT performance is conducted according to NEMA NU-1, and the performance does not change from the predicate device.
Verification and validation of Siemens systems is performed in accordance with documented procedures, design and code reviews, test plans and specifications. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software validation and system testing.
Statement regarding Substantial Equivalence:
Symbia Pro.specta VA20A systems are based on the commercially available Symbia Pro.specta VA10A systems and have the same indications for use as well as utilizes the same fundamental scientific technology as the predicate device. The software updates pose no new issues of safety and / or efficacy. Siemens considers the Symbia Pro.specta VA20A systems to be as safe and effective as the commercially available predicate device with substantially equivalent performance.